GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Change In Receivables

ALUR (Allurion Technologies) Change In Receivables : $9.76 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Change In Receivables?

Allurion Technologies's change in receivables for the quarter that ended in Sep. 2024 was $2.79 Mil. It means Allurion Technologies's Accounts Receivable declined by $2.79 Mil from Jun. 2024 to Sep. 2024 .

Allurion Technologies's change in receivables for the fiscal year that ended in Dec. 2023 was $-1.32 Mil. It means Allurion Technologies's Accounts Receivable increased by $1.32 Mil from Dec. 2022 to Dec. 2023 .

Allurion Technologies's Accounts Receivable for the quarter that ended in Sep. 2024 was $9.94 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Allurion Technologies's Days Sales Outstanding for the three months ended in Sep. 2024 was 168.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Allurion Technologies's liquidation value for the three months ended in Sep. 2024 was $-77.10 Mil.


Allurion Technologies Change In Receivables Historical Data

The historical data trend for Allurion Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Change In Receivables Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
Change In Receivables
-0.93 -22.82 -1.32

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.81 2.57 1.67 2.74 2.79

Allurion Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies  (NYSE:ALUR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Allurion Technologies's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=9.935/5.367*91
=168.92

2. In Ben Graham's calculation of liquidation value, Allurion Technologies's accounts receivable are only considered to be worth 75% of book value:

Allurion Technologies's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=28.654-115.489+0.75 * 9.935+0.5 * 4.568
=-77.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760